Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma...

Por Morris, John C., Tan, Antoinette R., Olencki, Thomas E., Shapiro, Geoffrey I., Dezube, Bruce J., Reiss, Michael, Hsu, Frank J., Berzofsky, Jay A., Lawrence, Donald P.
Publicado em 2014

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

Por Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Publicado em 2013

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Por Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Publicado no Oncologist (2015)

An Open-label, Dose-Escalation Phase 1 Study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma

Por Khalil, Danny N., Postow, Michael A., Ibrahim, Nageatte, Ludwig, Dale L., Cosaert, Jan, Kambhampati, Siva Rama Prasad, Tang, Shande, Grebennik, Dmitri, Kauh, John Sae Wook, Lenz, Heinz-Josef, Flaherty, Keith T., Hodi, F. Stephen, Lawrence, Donald P., Wolchok, Jedd D.
Publicado no Clin Cancer Res (2016)

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

Por Friedman, Adam A., Amzallag, Arnaud, Pruteanu-Malinici, Iulian, Baniya, Subash, Cooper, Zachary A., Piris, Adriano, Hargreaves, Leeza, Igras, Vivien, Frederick, Dennie T., Lawrence, Donald P., Haber, Daniel A., Flaherty, Keith T., Wargo, Jennifer A., Ramaswamy, Sridhar, Benes, Cyril H., Fisher, David E.
Publicado no PLoS One (2015)

Isolation and Molecular Characterization of Circulating Melanoma Cells

Por Luo, Xi, Mitra, Devarati, Sullivan, Ryan J., Wittner, Ben S., Kimura, Anya M., Pan, Shiwei, Hoang, Mai P., Brannigan, Brian W., Lawrence, Donald P., Flaherty, Keith T., Sequist, Lecia V., McMahon, Martin, Bosenberg, Marcus W., Stott, Shannon L., Ting, David T., Ramaswamy, Sridhar, Toner, Mehmet, Fisher, David E., Maheswaran, Shyamala, Haber, Daniel A.
Publicado em 2014

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Por Frederick, Dennie Tompers, Piris, Adriano, Cogdill, Alexandria P., Cooper, Zachary A., Lezcano, Cecilia, Ferrone, Cristina R., Mitra, Devarati, Boni, Andrea, Newton, Lindsay P., Liu, Chengwen, Peng, Weiyi, Sullivan, Ryan J, Lawrence, Donald P., Hodi, F. Stephen, Overwijk, Willem W., Lizée, Gregory, Murphy, George F., Hwu, Patrick, Flaherty, Keith T., Fisher, David E., Wargo, Jennifer A.
Publicado em 2013

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering...

Por Luke, Jason J., Callahan, Margaret K., Postow, Michael A., Romano, Emanuela, Ramaiya, Nikhil, Bluth, Mark, Giobbie-Hurder, Anita, Lawrence, Donald P., Ibrahim, Nageatte, Ott, Patrick A., Flaherty, Keith T., Sullivan, Ryan J., Harding, James J., D'Angelo, Sandra, Dickson, Mark, Schwartz, Gary K., Chapman, Paul B., Wolchok, Jedd D., Hodi, F. Stephen, Carvajal, Richard D.
Publicado em 2013

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Por Herbst, Roy S., Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F., Powderly, John D., Gettinger, Scott N., Kohrt, Holbrook E. K., Horn, Leora, Lawrence, Donald P., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hodi, F. Stephen
Publicado no Nature (2014)

Ipilimumab for Patients With Advanced Mucosal Melanoma

Por Postow, Michael A., Luke, Jason J., Bluth, Mark J., Ramaiya, Nikhil, Panageas, Katherine S., Lawrence, Donald P., Ibrahim, Nageatte, Flaherty, Keith T., Sullivan, Ryan J., Ott, Patrick A., Callahan, Margaret K., Harding, James J., D'Angelo, Sandra P., Dickson, Mark A., Schwartz, Gary K., Chapman, Paul B., Gnjatic, Sacha, Wolchok, Jedd D., Hodi, F. Stephen, Carvajal, Richard D.
Publicado em 2013

Clinical utility of a blood-based BRAF V600E mutation assay in melanoma

Por Panka, David J, Buchbinder, Elizabeth, Giobbie-Hurder, Anita, Schalck, Aislyn P, Montaser-Kouhsari, Laleh, Sepehr, Alireza, Lawrence, Donald P., McDermott, David F., Cohen, Rachel, Carlson, Alexander, Wargo, Jennifer A, Merritt, Ryan, Seery, Virginia J., Hodi, F. Stephen, Gunturi, Anasuya, Fredrick, Dennie, Atkins, Michael B., Iafrate, A. John, Flaherty, Keith T., Mier, James W, Sullivan, Ryan J
Publicado no Mol Cancer Ther (2014)

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Por Carvajal, Richard D., Lawrence, Donald P., Weber, Jeffrey S., Gajewski, Thomas F., Gonzalez, Rene, Lutzky, Jose, O’Day, Steven J., Hamid, Omid, Wolchok, Jedd D., Chapman, Paul B., Sullivan, Ryan J., Teitcher, Jerrold B., Ramaiya, Nikhil, Giobbie-Hurder, Anita, Antonescu, Cristina R., Heinrich, Michael C., Bastian, Boris C., Corless, Christopher L., Fletcher, Jonathan A., Hodi, F. Stephen
Publicado no Clin Cancer Res (2015)

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Por Topalian, Suzanne L., Sznol, Mario, McDermott, David F., Kluger, Harriet M., Carvajal, Richard D., Sharfman, William H., Brahmer, Julie R., Lawrence, Donald P., Atkins, Michael B., Powderly, John D., Leming, Philip D., Lipson, Evan J., Puzanov, Igor, Smith, David C., Taube, Janis M., Wigginton, Jon M., Kollia, Georgia D., Gupta, Ashok, Pardoll, Drew M., Sosman, Jeffrey A., Hodi, F. Stephen
Publicado no J Clin Oncol (2014)

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

Por Johnson, Douglas B., Flaherty, Keith T., Weber, Jeffrey S., Infante, Jeffrey R., Kim, Kevin B., Kefford, Richard F., Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H., McWilliams, Robert R., Sznol, Mario, Lawrence, Donald P., Gibney, Geoffrey T., Burris, Howard A., Falchook, Gerald S., Algazi, Alain, Lewis, Karl, Long, Georgina V., Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A., Daud, Adil, Gonzalez, Rene
Publicado no J Clin Oncol (2014)

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

Por Wagle, Nikhil, Van Allen, Eliezer M., Treacy, Daniel J., Frederick, Dennie T., Cooper, Zachary A., Taylor-Weiner, Amaro, Rosenberg, Mara, Goetz, Eva M., Sullivan, Ryan J., Farlow, Deborah N., Friedrich, Dennis C., Anderka, Kristin, Perrin, Danielle, Johannessen, Cory M., McKenna, Aaron, Cibulskis, Kristian, Kryukov, Gregory, Hodis, Eran, Lawrence, Donald P., Fisher, Sheila, Getz, Gad, Gabriel, Stacey B., Carter, Scott L., Flaherty, Keith T., Wargo, Jennifer A., Garraway, Levi A.
Publicado em 2013